NorthStar to buy accelerator for actinium-225 production

By staff writers

November 18, 2021 -- NorthStar Medical Radioisotopes has inked a deal with Ion Beam Applications (IBA) to purchase one of IBA's Rhodotron TT300 HE electron-beam accelerators for the commercial production of actinium-225 (Ac-225) at its new production facility in Beloit, WI.

Final designs are underway for the facility, which will be exclusively dedicated to Ac-225 production, NorthStar said. Initial production of Ac-225 is planned for late 2023, with a drug master file to be submitted to the U.S. Food and Drug Administration in 2024, the company said.

NorthStar's process for producing Ac-225 is free of long-life radioactive byproducts associated with other production methods, the company added.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking